Next-Gen Incretin Drugs: What Research Shows

Key Takeaways

A historical review in Biologie aujourd’hui traces how GLP-1 and GIP moved from basic hormone research to multi-indication ‘Swiss-army knife’ medications over four decades.
A real-world retrospective of the All of Us Research Program found meaningful differences in weight loss outcomes among approved GLP-1 receptor agonists in a diverse U.S. population.
A systematic review and meta-analysis in Cureus found that patients regained a substantial portion of lost weight after stopping weight-management medications, underscoring the chronic-disease framing of obesity.
Preclinical computational work published in the Journal of Computer-Aided Molecular Design describes a metabolically stable peptide designed to activate GLP-1, GIP, and glucagon receptors simultaneously.
A QbD-based formulation study in Pharmaceutics demonstrated a proof-of-concept oral tirzepatide tablet using sodium caprate to overcome gastric barriers in preclinical models.

From Gut Hormone to Blockbuster: A 40-Year Arc

GLP-1’s journey from an obscure intestinal signal to the backbone of a multi-billion-dollar drug class spans roughly four decades of incremental biochemical detective work, beginning with the identification of the incretin effect in the early 1980s and culminating in approved dual- and triple-agonist therapies in the 2020s. The arc is not a straight line — it is a series of hard pivots driven by unexpected biology.

Researchers first characterized glucagon-like peptide-1 as a product of the proglucagon gene expressed in intestinal L-cells, observing that it stimulated insulin secretion in a glucose-dependent manner, a property that distinguished it sharply from older insulin secretagogues that carried hypoglycemia risk. That glucose-dependency became the pharmacological foundation everything else was built on, as detailed in this historical incretin overview.

The early clinical problem was brutal simplicity: native GLP-1 has a plasma half-life of roughly two minutes, degraded almost instantly by the enzyme DPP-4. Drug development required either DPP-4 inhibition or structural re-engineering of the peptide itself. Chemists chose both paths simultaneously, producing two distinct drug classes from the same biological insight.

Key milestones in the incretin drug arc:

1980s: Researchers identify the incretin effect; GLP-1 isolated and sequenced from intestinal tissue, per the historical incretin overview
1990s–2000s: Exendin-4, a GLP-1 receptor agonist found in Gila monster saliva, demonstrates DPP-4 resistance in preclinical models — a serendipitous structural clue, noted in the same historical incretin overview
2005–2010s: First-generation GLP-1 receptor agonists enter clinical use for type 2 diabetes; weight loss emerges as a secondary signal researchers had not fully anticipated
2020s: Dual GIP/GLP-1 agonism (tirzepatide) and experimental triple agonism targeting GLP-1, GIP, and glucagon receptors simultaneously enter the picture, with preclinical peptide design work showing metabolic stability can be engineered into a single molecule, per this triple-agonist design study

The appetite-regulation dimension deepened the story considerably. GLP-1 does not act on the gut alone — it engages hypothalamic and brainstem circuits that govern satiety, situating it within a far larger peptide appetite network that researchers are still mapping.

What the 40-year arc reveals is a recurring pattern: a hormone studied for one purpose — glucose control — kept disclosing new biology, and each disclosure opened a new therapeutic door. The blockbuster status was not predicted. It was discovered.

Disclaimer: This article is for informational purposes only and does not constitute medical advice, treatment recommendations, or clinical guidance of any kind.

Real-World Weight Loss: How Do the Agents Compare?

In real-world clinical data, tirzepatide — a dual GIP/GLP-1 receptor agonist — outperformed every single GLP-1 receptor agonist studied for weight loss, with semaglutide ranking second among the GLP-1-only agents. A large retrospective cohort study drawing on the All of Us Research Program documented this hierarchy consistently across patient subgroups, making it one of the most comprehensive real-world comparisons published to date.

The All of Us retrospective cohort tracked weight outcomes across multiple approved agents:

Agent	Receptor Target(s)	Real-World Weight Loss Ranking
Tirzepatide	GIP + GLP-1	Highest
Semaglutide	GLP-1	Second
Other GLP-1 RAs	GLP-1	Lower

Mechanism explains the gap. Tirzepatide’s dual action on both GIP and GLP-1 receptors appears to drive greater appetite suppression and metabolic benefit than GLP-1 stimulation alone — a distinction that historical incretin reviews trace back to decades of research showing GIP and GLP-1 work through complementary, partially non-overlapping pathways.

Weight loss numbers tell only part of the story. Stopping counts.

A systematic review and meta-analysis examining post-cessation outcomes found that patients regain substantial weight after discontinuing weight-management medications. This pattern held across drug classes and follow-up periods. The multisystem disease framing of obesity, now increasingly adopted in clinical research, supports exactly this interpretation: chronic pharmacotherapy, not a finite course, may be what sustained benefit requires.

Researchers are already pushing beyond dual agonism. Preclinical work on triple-hormone-receptor agonists — peptides designed to hit GLP-1, GIP, and glucagon receptors simultaneously in animal models — has produced metabolically stable candidates, with investigators reporting favorable pharmacokinetic profiles. Whether that translates to greater human weight loss than tirzepatide remains an open question; no head-to-head clinical data exist yet.

Appetite regulation itself is a dense network of peptide hormones, not a single dial to turn. That complexity is precisely why agents hitting more receptor targets keep generating scientific interest — and why real-world comparisons like the All of Us study are so valuable for grounding preclinical excitement in patient outcomes.

Disclaimer: This article is for informational purposes only and does not constitute medical advice, treatment recommendations, or dosing guidance. Consult a qualified healthcare provider for any medical decisions.

The Rebound Problem: What Happens After Stopping

When people stop taking GLP-1 receptor agonist peptides, clinical evidence shows they regain a substantial portion of lost weight — often the majority of it — within months. That pattern points to a core biological reality: these peptides manage a chronic condition rather than cure it.

A 2025 systematic review and meta-analysis examining post-cessation outcomes across weight management medications found that weight regain after stopping is rapid and substantial, with participants recovering a large fraction of their lost weight within one to two years of discontinuation. The review’s findings reinforce what obesity researchers have argued for years — that the underlying physiology driving excess weight accumulation does not resolve during treatment.

Why does this happen? The answer lives in appetite-regulating biology. A complex network of peptide hormones — including ghrelin, leptin, GIP, and GLP-1 itself — governs hunger, satiety, and energy storage. That network (https://pubmed.ncbi.nlm.nih.gov/42515672/) does not permanently recalibrate after a course of exogenous peptide therapy ends. Remove the pharmacological signal, and the system reverts.

Obesity itself compounds the problem. Research framing obesity as a multisystem disease describes how adipose tissue dysfunction, neurohormonal dysregulation, and metabolic adaptation all persist independently of short-term weight loss — meaning the biological pressure to regain is structural, not simply behavioral.

Several implications follow directly from the rebound data:

Chronic use may be necessary for sustained effect. The systematic review frames post-cessation regain as evidence that GLP-1-based therapies function more like antihypertensives — ongoing management tools — than finite interventions.
Next-generation peptides are being designed with durability in mind. Preclinical research on a triple-hormone-receptor agonist — targeting GLP-1, GIP, and glucagon receptors simultaneously — aims partly to achieve stronger, more durable metabolic effects, though whether that translates to reduced rebound after stopping remains untested in humans. ** ** **
Real-world discontinuation rates are high. A retrospective cohort study using the All of Us Research Program found that real-world GLP-1 agonist use is marked by frequent treatment gaps, meaning rebound is not a theoretical edge case — it is a common clinical experience.

Rebound is not failure. It is physiology. The historical arc of incretin science shows that GLP-1 was always understood as a transient hormonal signal; engineering its pharmacological extension was the breakthrough, but no one claimed that extension would permanently rewire the system.

This article is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider for guidance on any medical treatment or condition.

Triple-Receptor Agonists and the Next Frontier

Triple-receptor agonists represent the leading edge of incretin-based peptide design. Preclinical research now demonstrates that a single engineered molecule can simultaneously activate GLP-1, GIP, and glucagon receptors to produce metabolic effects that exceed those seen with dual-agonist approaches. The architecture is deliberate.

Researchers designing these “triagonists” face a core engineering problem: GLP-1, GIP, and glucagon receptors each respond to structurally distinct peptide signals, yet all three belong to the same class B G-protein-coupled receptor family, which creates a narrow structural window where a single peptide sequence can be tuned to hit all three targets with meaningful potency. A 2025 preclinical study published in the peptide therapeutics literature reported the design of a metabolically stable triple-hormone-receptor agonist peptide that retained balanced activity across all three receptors while resisting enzymatic degradation — a persistent obstacle for peptide drugs in circulation.

Why glucagon? The rationale is thermogenic. Glucagon receptor activation drives energy expenditure in preclinical models, a mechanism that GLP-1 and GIP agonism alone does not robustly engage. The 2025 preclinical design study framed this combination as a strategy to address both caloric intake and caloric burn within a single molecular scaffold — an approach that, if it translates, could meaningfully shift the ceiling on weight reduction achievable through pharmacology.

The appetite-regulation network these molecules attempt to rewire is genuinely complex. A 2025 review of peptide hormones in appetite regulation described how gut-derived and centrally acting peptide signals interact across overlapping circuits, meaning that targeting multiple nodes simultaneously carries both therapeutic promise and unpredictable interaction risk. No triple-agonist molecule has yet completed large-scale human trials.

Key distinctions between receptor-targeting tiers, based on current preclinical and early clinical evidence:

GLP-1 mono-agonists (e.g., semaglutide): reduce appetite via hypothalamic and brainstem pathways; real-world cohort data confirm meaningful but variable weight loss across diverse populations
GLP-1/GIP dual-agonists (tirzepatide): add GIP-mediated insulin sensitization and adipose signaling; historical incretin review traces how this combination expanded the therapeutic concept beyond glycemic control
GLP-1/GIP/glucagon triple-agonists: preclinical stage; the 2025 design study reports enhanced metabolic stability and multi-receptor engagement in animal models — human data do not yet exist

The field is moving fast. Metabolic stability engineering, not just receptor pharmacology, will determine which candidates survive translation from animal model to clinical candidate.

Disclaimer: This article is for informational purposes only and does not constitute medical advice, treatment recommendations, or clinical guidance. Consult a qualified healthcare professional for any health-related decisions.

Oral Delivery and Adjunctive Strategies in Development

Oral peptide delivery remains an unsolved engineering problem, but a Quality-by-Design tablet formulation using sodium caprate as a permeation enhancer has demonstrated measurable tirzepatide absorption across gastric barrier models in preclinical work — and plant-derived bioactive compounds are simultaneously being evaluated as adjunctive strategies that may complement injectable peptide therapies.

The gastric environment destroys peptides. Acid, proteases, and mucus degrade most peptide drugs before they reach systemic circulation. Researchers developing an oral tirzepatide tablet deployed a QbD-based formulation approach to systematically optimize how sodium caprate — a medium-chain fatty acid — transiently opens tight junctions in gastrointestinal epithelium, enabling tirzepatide to cross. In laboratory barrier models, the optimized tablet formulation achieved statistically significant improvements in permeation compared with control formulations. Oral delivery matters enormously: injection burden is a documented reason patients discontinue therapy, and discontinuation drives the weight regain that a systematic review and meta-analysis found to be rapid and substantial after stopping weight-management medications.

A separate research track asks whether plant-derived compounds could amplify or sustain the effects of peptide-based therapies. A review of plant bioactives cataloged compounds — including berberine, quercetin, and resveratrol — that preclinical studies show can modulate GLP-1 secretion, reduce appetite signaling, or improve insulin sensitivity through mechanisms that partially overlap with incretin pathways. Key findings from that preclinical and in vitro evidence base:

Berberine activated GLP-1 secretion in intestinal cell models and improved glucose tolerance in rodent studies.
Quercetin reduced inflammatory signaling in adipose tissue in animal models, a pathway linked to appetite dysregulation.
Resveratrol modulated gut microbiota composition in preclinical work, with downstream effects on peptide YY and GLP-1 release.

None of these compounds have demonstrated clinical equivalence to approved peptide receptor agonists. The plant bioactives review frames them explicitly as adjunctive candidates, not replacements. The appetite-regulation network is dense and redundant, as a peptide hormone network review makes clear — single-target interventions rarely sustain long-term weight control, which is precisely why combination strategies are attracting research attention. Oral delivery and adjunctive compounds represent two distinct bets on the same underlying problem: making effective peptide-based obesity treatment more durable, more accessible, and less dependent on indefinite injection.

This section is for informational purposes only and does not constitute medical advice, treatment recommendations, or clinical guidance of any kind.

Obesity as a Multisystem Disease: Reframing the Science

Obesity is not a failure of willpower — it is a chronic, multisystem disease driven by dysregulated biology across the brain, gut, adipose tissue, and endocrine system. A 2025 review in Obesity Reviews makes this case explicitly, arguing that the field must abandon deficit-based framings and adopt a disease model that accounts for the full physiological complexity underlying excess adiposity.

The shift matters because it changes what researchers look for — and what they build.

The Obesity Reviews paper identifies several interlocking systems that obesity disrupts:

Central appetite regulation: Hypothalamic circuits governing hunger and satiety become dysregulated, blunting the normal feedback that would signal fullness.
Gut-brain signaling: Peptide hormones secreted from the gastrointestinal tract — including GLP-1, GIP, peptide YY, and ghrelin — form what a 2025 appetite-regulation review calls a complex network that coordinates meal-by-meal energy intake. Obesity alters the amplitude and timing of these signals.
Adipose tissue inflammation: Expanded fat depots become metabolically active in ways that amplify systemic inflammation and insulin resistance.
Metabolic adaptation: The body actively defends elevated weight set-points, a phenomenon that helps explain why patients who stop weight-management medications regain substantial weight across clinical studies — a systematic review and meta-analysis quantified this rebound effect across multiple drug classes.

These systems do not operate in isolation. The Obesity Reviews authors argue that treating any single pathway in isolation leaves the others intact and compensating — which is precisely why monotherapy approaches have historically produced modest, often transient results.

The diagnostic picture is equally complicated. The same review calls for redefining obesity criteria beyond BMI alone, pointing to evidence that adiposity-related organ dysfunction — not body weight per se — drives clinical risk. BMI misclassifies both lean individuals with metabolic disease and heavier individuals without it.

Researchers are responding to this complexity by designing therapeutics that engage multiple receptor systems simultaneously. A preclinical peptide design study engineered a single molecule with triple-hormone-receptor agonist activity — targeting GLP-1, GIP, and glucagon receptors at once — on the premise that coordinated multi-axis engagement produces metabolic effects in animal models that no single-receptor agent can replicate.

Obesity requires systems-level thinking.

This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations.

FAQ

What are incretin drugs and why are researchers so focused on them?

Incretins are gut-derived hormones—primarily GLP-1 and GIP—that stimulate insulin release and suppress appetite. A 2025 historical review in Biologie aujourd’hui describes how, over roughly four decades, researchers transformed these hormones into injectable and now potentially oral medications studied for type 2 diabetes, obesity, and a growing list of other conditions in clinical and preclinical settings.

Do all GLP-1 receptor agonists produce the same weight loss in real-world use?

Not according to a 2025 retrospective cohort study using the All of Us Research Program database. That study found differences in real-world weight outcomes across approved GLP-1 receptor agonists in a large, diverse U.S. population. However, the authors note that retrospective designs cannot establish causation and that individual factors varied across groups.

What does the research say about weight regain after stopping these medications?

A 2025 systematic review and meta-analysis in Cureus found that people regained a significant proportion of the weight they had lost after discontinuing weight-management medications. The authors frame this as evidence supporting the view—also articulated in a 2025 Nutrients review—that obesity is a chronic, multisystem disease rather than a short-term condition.

What is a triple-hormone-receptor agonist peptide and how far along is the research?

It is a computationally designed peptide intended to activate GLP-1, GIP, and glucagon receptors simultaneously. A 2025 paper in the Journal of Computer-Aided Molecular Design describes the design and preclinical modeling of such a molecule, emphasizing metabolic stability. This work is at an early preclinical stage, and no human efficacy or safety data exist yet.

Is an oral form of tirzepatide close to becoming available?

Researchers are exploring the possibility. A 2025 study in Pharmaceutics used a Quality-by-Design (QbD) framework to develop a tirzepatide tablet incorporating sodium caprate as a permeation enhancer to overcome gastric barriers. Results were demonstrated in preclinical models only; the work does not represent an approved product or confirm human bioavailability.

Are there non-peptide or plant-based approaches being studied alongside GLP-1 drugs?

Yes. A 2025 review in Nutrients examined plant-derived bioactive compounds as potential adjunctive strategies for obesity management, noting that some compounds interact with appetite-regulating pathways studied in preclinical models. The authors position these as complementary areas of investigation rather than replacements for approved therapies, and human evidence remains limited.

Note: This article is for general information and is not medical advice. Talk to a licensed clinician before using any peptide product.